NGM Biopharmaceuticals (NGM Biopharmaceuticals) Accumulated other comprehensive income (loss) : $0.02 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is NGM Biopharmaceuticals Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. NGM Biopharmaceuticals's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2023 was $0.02 Mil.

NGM Biopharmaceuticals's quarterly Accumulated other comprehensive income (loss) increased from Jun. 2023 ($-0.15 Mil) to Sep. 2023 ($-0.08 Mil) and increased from Sep. 2023 ($-0.08 Mil) to Dec. 2023 ($0.02 Mil).

NGM Biopharmaceuticals's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 ($-0.13 Mil) to Dec. 2022 ($-0.30 Mil) but then increased from Dec. 2022 ($-0.30 Mil) to Dec. 2023 ($0.02 Mil).

NGM Biopharmaceuticals Accumulated other comprehensive income (loss) Historical Data

The historical data trend for NGM Biopharmaceuticals's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NGM Biopharmaceuticals Accumulated other comprehensive income (loss) Chart

NGM Biopharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

0.03

-0.13

-0.30

0.02

NGM Biopharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															-0.30	-0.10	-0.15	-0.08	0.02

NGM Biopharmaceuticals Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

NGM Biopharmaceuticals Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of NGM Biopharmaceuticals's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

NGM Biopharmaceuticals (NGM Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NGM Biopharmaceuticals Inc (NAS:NGM) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

0IK:Germany

Address

333 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.ngmbio.com

NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease.

Executives

Column Group L P	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David V Goeddel	director, 10 percent owner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Jean-frederic Viret	officer: Chief Financial Officer	ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Irene Perlich	officer: Principal Accounting Officer	C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Jin-long Chen	director, officer: Chief Scientific Officer	630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Opportunity Iii Gp, Lp	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Tcg Opportunity Iii Gp, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Opportunity Iii, Lp	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Iv-a, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tcg Iv Gp, Llc	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii-a, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David J Woodhouse	director, officer: CEO and acting CFO	630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080